89852-17-5

Usage

Uses

Used in Pharmaceutical Synthesis:
Methyl 2-[(2S)-3-oxo-2,4,5,6-tetrahydropyrazin-2-yl]acetate is used as a key intermediate in the pharmaceutical industry for the synthesis of various drugs. Its unique structure and functional groups allow for the creation of bioactive molecules that can modulate biological pathways, making it an essential component in drug discovery and development processes.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, methyl 2-[(2S)-3-oxo-2,4,5,6-tetrahydropyrazin-2-yl]acetate is utilized as a building block for the development of potential drug candidates. Its ability to interact with biological systems and modulate pathways makes it a valuable tool for researchers working on the design and synthesis of new therapeutic agents.
Used in Organic Chemistry:
Methyl 2-[(2S)-3-oxo-2,4,5,6-tetrahydropyrazin-2-yl]acetate is also used in organic chemistry for the synthesis of a wide range of organic compounds. Its versatility and reactivity make it a popular choice for chemists working on the development of new materials and compounds with specific properties and applications.

InChI:InChI=1/C7H12N2O3/c1-12-6(10)4-5-7(11)9-3-2-8-5/h5,8H,2-4H2,1H3,(H,9,11)/p+1/t5-/m1/s1

Upstream product

• 624-48-6 dimethyl cis-but-2-ene-1,4-dioate 
• 107-15-3 ethylenediamine 

Downstream Products

• 1022918-57-5 6-(2-methoxyphenylcarboxamido)-1,3,4,8,9,9a-hexahydro-2H-pyrazino[1,2-c]pyrimidine-1,8-dione 
• 1023919-33-6 6-(2-ethylsulfanylphenylcarboxamido)-1,3,4,8,9,9a-hexahydro-2H-pyrazino[1,2-c]pyrimidine-1,8-dione 
• 1030830-40-0 6-(4-fluorophenylcarboxamido)-1,3,4,8,9,9a-hexahydro-2H-pyrazino[1,2-c]pyrimidine-1,8-dione 
• 1042692-92-1 6-phenylcarboxamido-1,3,4,8,9,9a-hexahydro-2H-pyrazino[1,2-c]pyrimidine-1,8-dione 
• 1030830-52-4 6-(4-methoxyphenylcarboxamido)-1,3,4,8,9,9a-hexahydro-2H-pyrazino[1,2-c]pyrimidine-1,8-dione 
• 828914-34-7 [3-oxo-1-(toluene-4-sulfonyl)-piperazin-2R-yl]-acetic acid 
• 405214-33-7 C₆H₁₀N₂O₃ 
• 1313202-32-2 C₈H₁₁N*C₁₃H₁₆N₂O₅S 
• 1313202-33-3 C₈H₁₁N*C₁₃H₁₆N₂O₅S 
• 1313202-05-9 C₃₀H₄₀N₄O₄S 
• 1313202-07-1 C₃₁H₄₂N₄O₄S 
• 1313202-08-2 C₂₄H₃₀N₄O₄S 

Relevant academic research and scientific papers

COMBINATION THERAPIES FOR TREATMENT OF CANCER

Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.

INHIBITORS OF KRAS G12C

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation

The discovery of novel and highly potent oxopiperazine based B1 receptor antagonists is described. Compared to the previously described arylsulfonylated (R)-3-amino-3-phenylpropionic acid series, the current compounds showed improved in vitro potency and